Services

Clinical research

Medaimun's clinical service covers the entire spectrum of planning, execution, and evaluation of drug substances in all stages of clinical development. Medaimun specializes particularly in Phase II studies, also known as "Proof of Concept" studies. Our clinical service includes:

Consulting

Protocol development

Patientenrekrutierung mit Studienproband.de

Site Service

Specialized examinations

Medical Writing

Protokollentwicklung

Asthma Protokolle

Prof Zielen, der medizinische Leiter ist ein weltweit anerkannter Asthmaspezialist. Er ist Mitglied der EAACI Working Group Diagnostik und Therapie des allergischen Asthma bronchiale, der deutschen Leitlinien Autoren für das Asthma bei Kindern und besonders versiert als Experte bei der bronchialen Allergenprovokation (1-3).

Mehrere Protokolle wurde von Ihm entwickelt und als Principal Investigator (PI) oder als National Koordinator geleitet.

  1. Effects of tregalizumab on allergen-induced airway responses and airway inflammation in asthmatic patients Phase 2 (Allergisches Asthma Alter 18-65 Jahre) 

        Sponsor: T-Balance

        EudraCT Number: 2020-000585-41.

 

  1. A prospective multicenter placebo-controlled trial to study the efficacy and safety of Tiotropium in preventing severe asthma exacerbations in partial and uncontrolled preschool asthma. TIPP-Study (Asthma Alter 1-5 Jahre)

        Sponsor: Goethe-Universität (IIT Prof. Zielen)

        EudraCT Number: 2021-000190-81

 

  1. Efficacy and Safety of QGE031 (Ligelizumab) versus Placebo and Omalizumab in patients aged 18-75 years with asthma (Asthma Alter 18-75 Jahre)

        Sponsor T-Balance: Novartis GmbH

        EudraCT Number:2020-000585-41.

        Eine genaue Analyse der Studie befindet sich in der Referenz 5. 

Referenzen:

  1. Medical algorithm: Diagnosis and treatment of house dust mite-driven allergic asthma. Schulze J, Agache I, Eguiluz-Gracia I, Trischler J, Zielen S. Allergy. 2023 May;78(5):1397-1399. doi: 10.1111/all.15654.
  2. EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities. Agache I, Antolin-Amerigo D, … et al. .Zielen S, Eguiluz- Gracia I. Allergy. 2022 Jun;77(6):1667-1684. doi: 10.1111/all. 15203.
  3. The late asthmatic reaction is in part independent from the early asthmatic reactions. Zielen S, Alemdar O, Wimmers A, Gronau L, Duecker R, Hutter M, Trischler J, Monchy JG, Schubert R. Int J Mol Sci. 2025 Feb 27;26(5):2088. doi: 10.3390/ijms26052088.
  4. Dual role of microRNA-146a in experimental inflammation in human pulmonary epithelial and immune cells and expression in inflammatory lung diseases. Gronau L, Duecker RP, Jerkic SP, Eickmeier O, Trischler J, Chiocchetti AG, Blumchen K, Zielen S, Schubert R. Int J Mol Sci. 2024 Jul 13;25(14):7686. doi: 10.3390/ijms25147686.
  5. Ligelizumab treatment for severe asthma: learnings from the clinical development programme. Trischler J, Bottoli I, Janocha R, Heusser C, Jaumont X, Lowe P, Gautier A, Pethe A, Woessner R, Zerwes HG, Zielen S. Clin Transl Immunology. 2021 Mar 15;10(3):e1255. doi: 10.1002/cti2.1255.

Medical consulting

We provide our clients with advice on all matters related to infectiology, pulmonology, and allergology. Our consulting services include:

Consulting in all phases of product development

Scientific consulting

Medical consulting

Approval processes support

Preparation of expert assessments

Literature research

Organization of training, seminars, and conferences

Schedule an appointment

Schedule your appointment with Prof. Dr. Zielen online